Nomura: Maintains a "buy" rating on SINOPHARM (01099) and lowers the target price to 25.09 Hong Kong dollars.
According to the estimate, the revenue of the company in the last quarter is expected to decrease by 0.4% year-on-year, while the profit is expected to drop by 2.8%.
Nomura released a research report stating that they maintain a "buy" rating for SINOPHARM (01099) with a target price lowered from 28.46 Hong Kong dollars to 25.09 Hong Kong dollars. The bank has lowered the group's sales forecast for 2024 and 2025 by 1.4% each, and reduced profit forecasts by 5.3% each to reflect profit pressure and credit losses or impairments. The bank estimates that Sinopharm's revenue in the last quarter will decrease by 0.4% year-on-year, while profits will drop by 2.8%.
Related Articles
ZYLOXTB (02190) expended approximately HK$1.2904 million to repurchase 50,000 shares on September 18.
CHINA PPT INV (00736): The company should explore and seek fundraising opportunities to support ongoing operations and business development.
On September 18, Midea Group Co., Ltd (00300) spent 280 million yuan to repurchase 3.7891 million A-shares.
ZYLOXTB (02190) expended approximately HK$1.2904 million to repurchase 50,000 shares on September 18.
CHINA PPT INV (00736): The company should explore and seek fundraising opportunities to support ongoing operations and business development.
On September 18, Midea Group Co., Ltd (00300) spent 280 million yuan to repurchase 3.7891 million A-shares.
